1 / 8

Thank you for downloading this update. Please feel free to use it for educational purposes.

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

kateb
Download Presentation

Thank you for downloading this update. Please feel free to use it for educational purposes.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. Authors:R. Rosell, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, F. Cardenal, R. Garcia Gomez, C. Pallares, J. Sanchez, R. Porta, M. Cobo, M. Di Seri, P. Garrido Lopez, A. Insa, F. De Marinis, R. Corre, M. Carreras, E. Carcereny, M. Taron, L. G. Paz-Ares, Spanish Lung Cancer Group J Clin Oncol 29: 2011 (suppl; abstr 7503) Reviewed by: Charles Butts Date posted: June 2011

  2. Thank you for downloading this update. Please feel free to use it for educational purposes. Please acknowledge OncologyEducation.ca and Dr. Charles Butts when using these slides.

  3. Study Design Study Question • In a randomized, prospective, Phase III study comparing erlotinib to Platinum based doublet chemo as first line therapy EGFR mutation positive Endpoints • Primary Endpoint • Progression free survival (PFS) • Secondary Endpoints • Overall survival (OS) • Objective Response Rate (ORR) Study Population • Stage IIIB/IV NSCLC, ECOG 0-2, chemo-naïve, EGFR mutation positive (exon 19/21)

  4. Study Design N= 174 Primary Outcome: PFS Erlotinib 150 mg daily until PD R Platinum doublet X 4 cycles • Stage IIIB/V • Chemo-naïve • Exon 19 del • Exon 21 L858R • ECOG 0-2 • Patient • Population

  5. Patient Characteristics

  6. RESULTS

  7. Study Commentary • 21% of patient samples tested were EGFR mutation positive • Overall survival no different but majority of patients crossed over at progression • No relevant safety concerns • First trial in western population to show erlotinib superior to chemo in terms of ORR and PFS in EGFR mutation positive patients.

  8. Bottom Line for Canadian Medical Oncologists • This is the first study in Caucasian population of EGFR TKI versus chemo as first line therapy • Further support for EGFR mutation analysis in appropriate patients • Those with activating mutations should be considered for first line GFR TKI therapy

More Related